Data to drugs.
What we do
We are an AI company with end-to-end capability from early drug discovery to late-stage clinical development. BenevolentAI has developed a truly integrated data and technology-driven approach to drug development, with a vast biomedical knowledge graph and a system that learns through each experimental loop in the drug discovery and development process, constantly becoming smarter and faster.
Our platform is designed to power target identification so we can find new ways to treat a disease, molecular design so we can develop the most effective medicines, and clinical mechanistic stratification so we can understand how individual patients will respond to treatment. We combine all three to generate new insights into the underlying causes of disease, as well as routes to new or more effective treatments.
From the outset our approach has brought together experts from technology, research and scientific domains to work side by side on better, faster ways to develop new medicines. This diversity, combined with our expertise and open working practices, creates a powerful environment for innovation and scientific breakthrough.
Why we do it
We built the Benevolent platform to better understand disease and to design new and better treatments from vast quantities of existing and inferred biomedical information. We believe our technology will empower scientists to develop medicines faster and more cost-efficiently.
Ninety percent of the world's data has been created in the last 2 years, wherein a new research paper is published every 30 seconds. Scientists are currently using only a fraction of the knowledge available to understand the cause of disease and propose new treatments.
Our platform ingests, 'reads' and contextualises vast quantities of information drawn from written documents, databases and experimental results. What's more, it is able to make infinitely more deductions and inferences across these disparate, complex data sources, identifying and creating relationships, trends and patterns, that would be impossible for a human being to make alone. Our platform is enabling us to evolve ideas at an unprecedented scale. As a result, scientists are able to design drugs and bring new treatments to patients, faster, with an increased likelihood of success in a process which is notoriously complex.
For every patient.
Where it happens.
We're headquartered in London’s ‘Knowledge Quarter,’ where our neighbours include Google, Facebook, the Alan Turing Institute, the Francis Crick Institute, UCL and the Wellcome Trust.
Our New York office opened this year and looks out onto the Brooklyn Bridge. The team is twenty-strong and growing, and works side-by-side within squads that span all our locations.
We operate our own state-of-the-art BenevolentAI drug discovery and development facility, on the world famous Babraham Research Campus, Cambridge UK.
We have a small but perfectly formed team of engineers in Antwerp, Belgium, led by Benevolent's SVP Technology.